Serum Biomarker Panels for the Diagnosis of Gastric Adenocarcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Jan 14

PMID 22240791

Citations 24

Authors

H S Ahn

Y S Shin

P J Park

K N Kang

Y Kim

H-J Lee

H-K Yang

C W Kim

Affiliations

Soon will be listed here.

Abstract

Background: Currently, serum biomarkers, which are sufficiently sensitive and specific for early detection and risk classification of gastric adenocarcinoma do not exist. Therefore, this study identified a panel of serum biomarkers for the diagnosis of gastric adenocarcinoma.

Methods: A 29-plex array platform with 29 biomarkers, consisting of 11 proteins discovered through proteomics and 18 previously known to be cancer-associated, was constructed. A test/training set consisting of 120 gastric adenocarcinoma and 120 control samples were examined. After 13 proteins were selected as candidate biomarkers, multivariate classification analyses were used to identify algorithms for diagnostic biomarker combinations. These algorithms were independently validated using a set of 95 gastric adenocarcinoma and 51 control samples.

Results: Epidermal growth factor receptor (EGFR), pro-apolipoprotein A1 (proApoA1), apolipoprotein A1, transthyretin (TTR), regulated upon activation, normally T-expressed and presumably secreted (RANTES), D-dimer, vitronectin (VN), interleukin-6, α-2 macroglobulin, C-reactive protein and plasminogen activator inhibitor-1 were selected as classifiers in the two algorithms. These algorithms differentiated between the majority of gastric adenocarcinoma and control serum samples in the training/test set with high accuracy (>88%). These algorithms also accurately classified in the validation set (>85%).

Conclusion: Two panels of combinatorial biomarkers, including EGFR, TTR, RANTES, and VN, are developed, which are less invasive method for the diagnosis of gastric adenocarcinoma. They could supplement clinical gastroscopic evaluation of symptomatic patients to enhance diagnostic accuracy.

Citing Articles

Explainable machine learning models for early gastric cancer diagnosis.

Du H, Yang Q, Ge A, Zhao C, Ma Y, Wang S Sci Rep. 2024; 14(1):17457.

PMID: 39075116 PMC: 11286780. DOI: 10.1038/s41598-024-67892-z.

PG I and PG II show unique value in diagnosing postoperative biochemical recurrence in patients with gastric cancer after total gastrectomy.

Zhang J, Liu J, Dong L, Wang X, Mao X, Mao Y Discov Oncol. 2024; 15(1):231.

PMID: 38884851 PMC: 11183004. DOI: 10.1007/s12672-024-01091-0.

Proteomics appending a complementary dimension to precision oncotherapy.

Zhou Z, Zhang R, Zhou A, Lv J, Chen S, Zou H Comput Struct Biotechnol J. 2024; 23:1725-1739.

PMID: 38689716 PMC: 11058087. DOI: 10.1016/j.csbj.2024.04.044.

Painless and sensitive pepsinogen I detection: an electrochemical immunosensor based on rhombic dodecahedral CuPt and MoS NFs.

Wei S, Li S, Xiao H, Zhao F, Zhu J, Chen Z Nanoscale Adv. 2023; 5(1):133-141.

PMID: 36605809 PMC: 9765571. DOI: 10.1039/d2na00556e.

Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening.

Kang K, Koh E, Jang J, Kim C Obstet Gynecol Sci. 2022; 65(4):346-354.

PMID: 35443557 PMC: 9304440. DOI: 10.5468/ogs.22017.

References

Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y . Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003; 98(4):735-9. DOI: 10.1111/j.1572-0241.2003.07410.x. View

Kim D, Oh S, Kwon H, Lee S, Kwon K, Kim B . Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009; 9:155. PMC: 2694817. DOI: 10.1186/1471-2407-9-155. View

Gotoda T . Endoscopic resection of early gastric cancer. Gastric Cancer. 2007; 10(1):1-11. DOI: 10.1007/s10120-006-0408-1. View

Kodama I, Koufuji K, Kawabata S, Tetsu S, Tsuji Y, Takeda J . The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA. Int Surg. 1995; 80(1):45-8. View

Forones N, Mandowsky S, Lourenco L . Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology. 2001; 48(40):1199-201. View

Lim J, Cho J, Paik Y, Chang Y, Kim H . Diagnostic application of serum proteomic patterns in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Biol Markers. 2007; 22(4):281-6. DOI: 10.1177/172460080702200407. View

Maniatis A, Eisen G, Brazer S . Endoscopic discrimination of gastric ulcers. J Clin Gastroenterol. 1997; 24(4):203-6. DOI: 10.1097/00004836-199706000-00004. View

Juhasz M, Ebert M, Schulz H, Rocken C, Molnar B, Tulassay Z . Dual role of serum soluble E-cadherin as a biological marker of metastatic development in gastric cancer. Scand J Gastroenterol. 2003; 38(8):850-5. DOI: 10.1080/00365520310003985. View

Gaspar M, Arribas I, Coca M . Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol. 2001; 22(5):318-22. DOI: 10.1159/000050633. View

10.

Raftopoulos S, Segarajasingam D, Burke V, Ee H, Yusoff I . A cohort study of missed and new cancers after esophagogastroduodenoscopy. Am J Gastroenterol. 2010; 105(6):1292-7. DOI: 10.1038/ajg.2009.736. View

11.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

12.

Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y . Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer. 2009; 12(2):95-100. DOI: 10.1007/s10120-009-0509-8. View

13.

Bramble M, Suvakovic Z, Hungin A . Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut. 2000; 46(4):464-7. PMC: 1727877. DOI: 10.1136/gut.46.4.464. View

14.

Amin A, Gilmour H, Graham L, Paterson-Brown S, Terrace J, Crofts T . Gastric adenocarcinoma missed at endoscopy. J R Coll Surg Edinb. 2002; 47(5):681-4. View

15.

Kong S, Park D, Lee H, Jung H, Lee K, Choe K . Clinicopathologic features of asymptomatic gastric adenocarcinoma patients in Korea. Jpn J Clin Oncol. 2004; 34(1):1-7. DOI: 10.1093/jjco/hyh009. View

16.

Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F . Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010; 28(13):2159-66. PMC: 2860434. DOI: 10.1200/JCO.2008.19.2484. View

17.

Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F . Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001; 181(1):16-9. DOI: 10.1016/s0002-9610(00)00549-3. View

18.

Furey T, Cristianini N, Duffy N, Bednarski D, Schummer M, Haussler D . Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics. 2000; 16(10):906-14. DOI: 10.1093/bioinformatics/16.10.906. View

19.

Nolen B, Marks J, Tasan S, Rand A, Luong T, Wang Y . Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res. 2008; 10(3):R45. PMC: 2481492. DOI: 10.1186/bcr2096. View

20.

Yuan A, Chen J, Yang P . Pathophysiology of tumor-associated macrophages. Adv Clin Chem. 2008; 45:199-223. View